Amy L Jonson

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. doi Gonadal dysgenesis and gynecologic cancer
    Amy L Jonson
    Division of Gynecologic Oncology, University of Minnesota Department of Obstetrics, Gynecology, Women s Health, Minneapolis, Minnesota, USA
    Obstet Gynecol 116:550-2. 2010
  2. doi Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study
    Peter A Argenta
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 129:81-5. 2013
  3. doi Learning about ovarian cancer at the time of diagnosis: video versus usual care
    Melissa A Geller
    Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 119:370-5. 2010
  4. doi A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 121:112-7. 2011
  5. pmc A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
    Melissa A Geller
    Obstetrics and Gynecology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Cytotherapy 13:98-107. 2011
  6. doi Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer
    Amy L Jonson
    University of Minnesota Medical School, Department of Obstetrics, Gynecology and Women s Health, 420 Delaware Street S E, MMC 395, Minneapolis, MN 55455 0374, USA
    Gynecol Oncol 111:356-64. 2008
  7. doi A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Minneapolis MN 55455, USA
    Gynecol Oncol 113:205-9. 2009

Detail Information

Publications7

  1. doi Gonadal dysgenesis and gynecologic cancer
    Amy L Jonson
    Division of Gynecologic Oncology, University of Minnesota Department of Obstetrics, Gynecology, Women s Health, Minneapolis, Minnesota, USA
    Obstet Gynecol 116:550-2. 2010
    ..Gonadal dysgenesis encompasses a variety of sexual differentiation disorders. Within this population of patients, there is an increased risk of gonadal tumor formation...
  2. doi Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study
    Peter A Argenta
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 129:81-5. 2013
    ..We aimed to evaluate the feasibility and tolerability of hyperthermic intraperitoneal carboplatin (HIPEC-carboplatin) following secondary cytoreduction for recurrent, platinum-sensitive ovarian cancer...
  3. doi Learning about ovarian cancer at the time of diagnosis: video versus usual care
    Melissa A Geller
    Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 119:370-5. 2010
    ..We evaluated the effects of an educational video on patients' distress, cancer knowledge, coping skills and attitudes regarding learning about cancer at the time of ovarian cancer diagnosis...
  4. doi A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
    Gynecol Oncol 121:112-7. 2011
    ..To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer...
  5. pmc A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
    Melissa A Geller
    Obstetrics and Gynecology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Cytotherapy 13:98-107. 2011
    ..We evaluated the tumor response and in vivo expansion of allogeneic NK cells in recurrent ovarian and breast cancer...
  6. doi Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer
    Amy L Jonson
    University of Minnesota Medical School, Department of Obstetrics, Gynecology and Women s Health, 420 Delaware Street S E, MMC 395, Minneapolis, MN 55455 0374, USA
    Gynecol Oncol 111:356-64. 2008
    ..Our objective was to determine if siRNA targeting E6/E7 would inhibit the growth of established tumors in a mouse model of cervical cancer...
  7. doi A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer
    Peter A Argenta
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Minneapolis MN 55455, USA
    Gynecol Oncol 113:205-9. 2009
    ..Grade 1 toxicity included headache (1 patient) and bromidrosis (2 patients). Conclusions. Fulvestrant is well-tolerated and efficacious. Objective response rates are low, but disease stabilization was common...